All In Biotech

Drug Trial Radar · NCT05084508

A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age

A Phase II, Observer-blind, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of a Varicella Vaccine at Various Potencies Compared With Varivax, as a First Dose, Administered in Healthy Children in Their Second Year of Life

Last checked: Nov 20, 2026Latest source record: Feb 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 800 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

800

Actual

Start

Feb 3, 2022

Primary completion

Feb 9, 2024

Study completion Jun 13, 2024

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Oct 19, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 12 months, up to 15 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess immune response and safety of various potencies of an investigational chickenpox vaccine given to healthy children 12 to 15 months of age.

Conditions

  • Chickenpox

Interventions

  • Investigational varicella vaccine low potencyBiological

    1 dose of a low-potency investigational varicella vaccine administered subcutaneously.

  • Investigational varicella vaccine medium potencyBiological

    1 dose of a medium-potency investigational varicella vaccine administered subcutaneously.

  • Investigational varicella vaccine high potencyBiological

    1 dose of a high-potency investigational varicella vaccine administered subcutaneously.

  • Licensed varicella vaccine Lot 1Biological

    1 dose of a licensed varicella vaccine of Lot 1 administered subcutaneously.

  • Licensed varicella vaccine Lot 2Biological

    1 dose of a licensed varicella vaccine of Lot 2 administered subcutaneously.

  • Measles, mumps, and rubella vaccineBiological

    1 dose of a measles, mumps, and rubella vaccine administered subcutaneously.

  • Hepatitis A vaccineBiological

    1 dose of a hepatitis A vaccine administered intramuscularly.

  • 13-valent pneumococcal conjugate vaccineBiological

    1 dose of a 13-valent pneumococcal conjugate vaccine administered intramuscularly.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Concentrations of Anti-varicella Zoster Virus (VZV) Glycoprotein E (gE) AntibodiesTime frame: At Day 43

Locations

51 sites in 6 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Bryant, Arkansas

  • GSK Investigational Site

    Jonesboro, Arkansas

  • GSK Investigational Site

    Little Rock, Arkansas

  • GSK Investigational Site

    Bellflower, California

  • GSK Investigational Site

    Downey, California

  • GSK Investigational Site

    Foothill Ranch, California

  • GSK Investigational Site

    Huntington Park, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    West Covina, California

  • GSK Investigational Site

    Tampa, Florida

  • GSK Investigational Site

    Atlanta, Georgia

  • GSK Investigational Site

    Idaho Falls, Idaho

  • GSK Investigational Site

    New Orleans, Louisiana

  • GSK Investigational Site

    Gulfport, Mississippi

  • GSK Investigational Site

    Bridgeton, Missouri

  • GSK Investigational Site

    Omaha, Nebraska

  • GSK Investigational Site

    Omaha, Nebraska

  • GSK Investigational Site

    Las Vegas, Nevada

  • GSK Investigational Site

    East Syracuse, New York

  • GSK Investigational Site

    The Bronx, New York

  • GSK Investigational Site

    Charlotte, North Carolina

  • GSK Investigational Site

    Cleveland, Ohio

  • GSK Investigational Site

    Dayton, Ohio

  • GSK Investigational Site

    Fort Washington, Pennsylvania

  • GSK Investigational Site

    Barnwell, South Carolina

  • GSK Investigational Site

    Tullahoma, Tennessee

  • GSK Investigational Site

    Corpus Christi, Texas

  • GSK Investigational Site

    Dallas, Texas

  • GSK Investigational Site

    Dickinson, Texas

  • GSK Investigational Site

    Houston, Texas

  • GSK Investigational Site

    McAllen, Texas

  • GSK Investigational Site

    Pflugerville, Texas

  • GSK Investigational Site

    San Antonio, Texas

  • GSK Investigational Site

    Layton, Utah

  • GSK Investigational Site

    Provo, Utah

  • GSK Investigational Site

    Roy, Utah

  • GSK Investigational Site

    South Jordan, Utah

  • GSK Investigational Site

    St. George, Utah

  • GSK Investigational Site

    Syracuse, Utah

  • GSK Investigational Site

    Charlottesville, Virginia

Showing 40 of 51 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.